Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)

Historic Work In Process for Protagonist Therapeutics (PTGX) over the last 4 years, with Q4 2024 value amounting to $165.0 million.

  • Protagonist Therapeutics' Work In Process rose 155000.0% to $165.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $165.0 million, marking a year-over-year increase of 155000.0%. This contributed to the annual value of $165.0 million for FY2024, which is 155000.0% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Work In Process stood at $165.0 million for Q4 2024, which was up 155000.0% from $43000.0 recorded in Q2 2024.
  • Over the past 5 years, Protagonist Therapeutics' Work In Process peaked at $300.0 million during Q1 2024, and registered a low of $10000.0 during Q4 2022.
  • Its 4-year average for Work In Process is $68.1 million, with a median of $1.6 million in 2021.
  • Its Work In Process has fluctuated over the past 5 years, first tumbled by 9936.14% in 2022, then surged by 9990000.0% in 2023.
  • Protagonist Therapeutics' Work In Process (Quarter) stood at $1.6 million in 2021, then tumbled by 99.36% to $10000.0 in 2022, then soared by 99900.0% to $10.0 million in 2023, then soared by 1550.0% to $165.0 million in 2024.
  • Its last three reported values are $165.0 million in Q4 2024, $43000.0 for Q2 2024, and $300.0 million during Q1 2024.